NCT07276113 is a NA clinical trial of omega-3 enriched eggs in Suboptimal Omega-3 Index, sponsored by Queen's University, Belfast.

Who is sponsoring NCT07276113?

NCT07276113 is sponsored by Queen's University, Belfast.

What drugs are being tested in NCT07276113?

Interventions in NCT07276113: omega-3 enriched eggs, non-enriched eggs.

What condition does NCT07276113 study?

NCT07276113 studies Suboptimal Omega-3 Index.

Is NCT07276113 still recruiting?

NCT07276113 is currently completed. Last updated 10 December 2025.

Last reviewed 2025-12-10 · How we verify

NCT07276113

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Enriched Eggs as a Sustainable Approach to Enhance Omega-3 Status in Elite Athletes

Completed NA Last updated 10 December 2025

What this trial tests

NA trial testing omega-3 enriched eggs in Suboptimal Omega-3 Index in 17 participants. Completed in 31 December 2024.

Timeline

25 September 2023

Primary endpoint
9 December 2024

31 December 2024

Quick facts

Lead sponsor	Queen's University, Belfast
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	17
Start date	25 September 2023
Primary completion	9 December 2024
Estimated completion	31 December 2024
Sites	2 locations across United Kingdom, Ireland

Drugs / interventions tested

omega-3 enriched eggs
non-enriched eggs

Conditions studied

Suboptimal Omega-3 Index — all drugs for Suboptimal Omega-3 Index →

Sponsor

Queen's University, Belfast

Who can join

18 and older, any sex, with Suboptimal Omega-3 Index. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study looked to identify the benefit of omega-3 enriched eggs on circulating omega-3 fatty acid profile of elite level athletes

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Queen's University, Belfast trials

Trials by the same sponsor.

NCT07373041 — Heart Failure Carer Support Programme: Implementation Testing in the UK. · NA · not yet recruiting
NCT07482839 — Feasibility Study of a Compassionate Mindful Resilience (CMR) Intervention to Improve Mental Health Well-being Outcomes · NA · not yet recruiting
NCT07333924 — Randomised Study Within a Review (SWAR) to Compare Communication of the Findings of Systematic Reviews to the Public by · Phase 3 · completed
NCT06896799 — Determining the Effect of Food Ordering on Blood Glucose In Gestational Diabetes Mellitus (DEFI-GDM) · NA · recruiting
NCT06749327 — Dissecting the Roles of High-quality Diets and Ultra Processed Foods on Cardiometabolic Health · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07276113 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Queen's University, Belfast
Last refreshed: 10 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07276113.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing